Table 5.
Results of the Poisson regression models on days of hospital/ED associated CINV events
|
Parameters |
Breast cancer (N = 3606) |
Carboplatin-treated lung cancer (N = 4497) |
Cisplatin-treated lung cancer (N = 1154) |
|||
|---|---|---|---|---|---|---|
| Regression coefficient (95% CI) | P value | Regression coefficient (95% CI) | P value | Regression coefficient (95% CI) | P value | |
| Age |
-0.0032 (-0.0219; 0.0155) |
0.7354 |
-0.0008 (-0.0120; 0.0105) |
0.8961 |
-0.0149 (-0.0325; 0.0027) |
0.0968 |
| CCI |
0.2529 (0.0572; 0.4486) |
0.0113 |
0.0448 (0.0087; 0.0810) |
0.0151 |
0.0747 (0.0182; 0.1312) |
0.0096 |
| Gender (male as reference) | ||||||
| Female |
NA |
|
-0.1815 (-0.4202; 0.0573) |
0.1363 |
-0.0132 (-0.3975; 0.3711) |
0.9463 |
| Days with cyclophosphamide (in breast cancer) or carboplatin (in lung cancer) treatment |
-0.3800 (-0.5600; -0.2000) |
<.0001 |
-0.0483 (-0.0848; -0.0118) |
0.0095 |
0.0113 (-0.0263; 0.0488) |
0.5561 |
| Antiemetic regimen (older 5-HT3 RAs as reference) | ||||||
| Palonosetron | -0.6431 (-1.0391; -0.2471)* | 0.0015 | -0.3436 (-0.5871; -0.1001)* | 0.0057 | -0.0373 (-0.4456; 0.3711) | 0.8580 |
* In Poisson regression, the exponential of coefficient indicates the ratio of the comparison groups in outcome. The exponential of the coefficient of antiemetic regimen (-0.6431) was 0.526 in the BC cohort, indicating the average CINV-hospitalization/ED days of palonosetron group was about 52.6% of that of the comparison group (older 5-HT3 RAs). The exponential of the coefficient of antiemetic regimen (-0.3436) was 0.709 in the LC-carboplatin cohort, indicating the average CINV-hospitalization/ED days of palonosetron group was about 70.9% of that of the comparison group (older 5-HT3 RAs).